Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD By Ogkologos - November 7, 2025 278 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATHENA-MONO/GOG-3020/ENGOT-ov45 study Source RELATED ARTICLESMORE FROM AUTHOR Consensus-Defined Weight Loss Episodes Arise in Discrete Intervals, Are Enriched Around Progression and Associated with Serologic Signatures and Somatic Tumour Genotypes ESMO launches new principles for humanising scientific reporting to strengthen the communication of cancer research Clinical Activity of Talazoparib Plus Enzalutamide Demonstrated in Patients with High-Volume mHNPC, but Without Clear Benefit Over Enzalutamide in Biomarker-Unselected Population MOST POPULAR Study Shows Supplements Increase Risk of Relapse and Death in Breast... January 7, 2020 How We’re Working to Build a Cancer Survivorship Community: Survivors’ Perspectives December 14, 2023 Identical Twins Get Mirror Cancer Diagnoses Within Three Weeks Of Each... August 15, 2019 Researchers Believe Antibodies from Alpacas Could Be Key to Curing Cancer,... August 15, 2019 Load more HOT NEWS Teacher’s Mental Health Check-In Board Goes Viral For The ‘Beautiful’ Standard... Grieving for Your Old Life After Cancer Checking in on our Mental Health Coping With the Difficult Times of Cancer Survivorship Through My “Bucket...
